Program
CM383
A development code.
Its studies are mostly in Alzheimer Disease, led by Keymed Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 22 open or running | phase 1since May 9, 2024 | May 9, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2024First study: phase 1 study in Alzheimer DiseaseFirst studyNCT06412185 · 56 planned · China
- Dec 3, 2025Phase 1 study in HealthyNCT07292688 · 30 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07292688Healthy · China | 1 | Recruiting | Jul 2026 | 30 |
| NCT06412185Alzheimer Disease · China | 1 | Recruiting | Jun 30, 2025 | 56 |
How it is read
Names in the registry
- “CM383”, 3 entries
Codes read as this program: CM383.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.